Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down – Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares gapped down prior to trading on Thursday . The stock had previously closed at $7.49, but opened at $7.24. Recursion Pharmaceuticals shares last traded at $7.18, with a volume of 3,042,116 shares changing hands.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on RXRX. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. KeyCorp lowered their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $8.75.

Recursion Pharmaceuticals Trading Up 1.5 %

The company has a market cap of $2.97 billion, a PE ratio of -4.97 and a beta of 0.85. The business has a 50 day simple moving average of $6.86 and a two-hundred day simple moving average of $6.94. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The firm had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company’s quarterly revenue was up 147.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.43) earnings per share. On average, analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current fiscal year.

Insider Activity

In other news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $6.72, for a total transaction of $76,923.84. Following the transaction, the director now owns 7,077,560 shares of the company’s stock, valued at approximately $47,561,203.20. This trade represents a 0.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Michael Secora sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total transaction of $114,900.00. Following the completion of the transaction, the chief financial officer now directly owns 1,499,631 shares in the company, valued at $11,487,173.46. This represents a 0.99 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 37,894 shares of company stock worth $279,279 over the last ninety days. Corporate insiders own 15.75% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of large investors have recently bought and sold shares of RXRX. Allspring Global Investments Holdings LLC bought a new position in Recursion Pharmaceuticals in the third quarter worth about $25,000. Decker Retirement Planning Inc. acquired a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $26,000. GAMMA Investing LLC increased its stake in shares of Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock valued at $35,000 after purchasing an additional 4,948 shares during the period. Farther Finance Advisors LLC increased its stake in shares of Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after purchasing an additional 4,091 shares during the period. Finally, KBC Group NV increased its stake in shares of Recursion Pharmaceuticals by 79.9% in the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after purchasing an additional 3,377 shares during the period. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.